BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 16946303)

  • 1. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival.
    Uddin S; Hussain AR; Siraj AK; Manogaran PS; Al-Jomah NA; Moorji A; Atizado V; Al-Dayel F; Belgaumi A; El-Solh H; Ezzat A; Bavi P; Al-Kuraya KS
    Blood; 2006 Dec; 108(13):4178-86. PubMed ID: 16946303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of XIAP expression in DLBCL and effect of its inhibition on AKT signalling.
    Hussain AR; Uddin S; Ahmed M; Bu R; Ahmed SO; Abubaker J; Sultana M; Ajarim D; Al-Dayel F; Bavi PP; Al-Kuraya KS
    J Pathol; 2010 Oct; 222(2):180-90. PubMed ID: 20632385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of phosphatidylinositol 3'-kinase/AKT signaling promotes apoptosis of primary effusion lymphoma cells.
    Uddin S; Hussain AR; Al-Hussein KA; Manogaran PS; Wickrema A; Gutierrez MI; Bhatia KG
    Clin Cancer Res; 2005 Apr; 11(8):3102-8. PubMed ID: 15837766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
    Xie X; Tang B; Zhou J; Gao Q; Zhang P
    Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
    Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.
    Smith PG; Wang F; Wilkinson KN; Savage KJ; Klein U; Neuberg DS; Bollag G; Shipp MA; Aguiar RC
    Blood; 2005 Jan; 105(1):308-16. PubMed ID: 15331441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.
    Petrich AM; Leshchenko V; Kuo PY; Xia B; Thirukonda VK; Ulahannan N; Gordon S; Fazzari MJ; Ye BH; Sparano JA; Parekh S
    Clin Cancer Res; 2012 May; 18(9):2534-44. PubMed ID: 22338016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lethal effects of pharmacological cyclin-dependent kinase inhibitors in human leukemia cells proceed through a phosphatidylinositol 3-kinase/Akt-dependent process.
    Yu C; Rahmani M; Dai Y; Conrad D; Krystal G; Dent P; Grant S
    Cancer Res; 2003 Apr; 63(8):1822-33. PubMed ID: 12702569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects of AKT protein kinase activation on biologic behavior of diffuse large B cell lymphoma cells].
    Zhang TC; Zhou XY; Yu BH; Zhang TM; Shi DR
    Zhonghua Bing Li Xue Za Zhi; 2007 May; 36(5):318-23. PubMed ID: 17706139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Leptin receptor expression and its association with PI3K/AKT signaling pathway in diffuse large B-cell lymphoma.
    Uddin S; Bu R; Ahmed M; Hussain AR; Ajarim D; Al-Dayel F; Bavi P; Al-kuraya KS
    Leuk Lymphoma; 2010 Jul; 51(7):1305-14. PubMed ID: 20443680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting of X-linked inhibitor of apoptosis protein and PI3-kinase/AKT signaling by embelin suppresses growth of leukemic cells.
    Prabhu KS; Siveen KS; Kuttikrishnan S; Iskandarani A; Tsakou M; Achkar IW; Therachiyil L; Krishnankutty R; Parray A; Kulinski M; Merhi M; Dermime S; Mohammad RM; Uddin S
    PLoS One; 2017; 12(7):e0180895. PubMed ID: 28704451
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
    Krystal GW; Sulanke G; Litz J
    Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential regulation of mTOR signaling determines sensitivity to AKT inhibition in diffuse large B cell lymphoma.
    Ezell SA; Wang S; Bihani T; Lai Z; Grosskurth SE; Tepsuporn S; Davies BR; Huszar D; Byth KF
    Oncotarget; 2016 Feb; 7(8):9163-74. PubMed ID: 26824321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of the PI3K/AKT/mTOR pathway in diffuse large B cell lymphoma: clinical significance and inhibitory effect of rituximab.
    Xu ZZ; Xia ZG; Wang AH; Wang WF; Liu ZY; Chen LY; Li JM
    Ann Hematol; 2013 Oct; 92(10):1351-8. PubMed ID: 23636313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphatidylinositol 3-kinase-Akt signaling in pulmonary carcinoid cells.
    Pitt SC; Chen H; Kunnimalaiyaan M
    J Am Coll Surg; 2009 Jul; 209(1):82-8. PubMed ID: 19651067
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K/AKT pathway in diffuse large B-cell lymphoma.
    Go H; Jang JY; Kim PJ; Kim YG; Nam SJ; Paik JH; Kim TM; Heo DS; Kim CW; Jeon YK
    Oncotarget; 2015 Jun; 6(17):15035-49. PubMed ID: 25909227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab inhibits the constitutively activated PI3K-Akt pathway in B-NHL cell lines: involvement in chemosensitization to drug-induced apoptosis.
    Suzuki E; Umezawa K; Bonavida B
    Oncogene; 2007 Sep; 26(42):6184-93. PubMed ID: 17420722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung.
    Qian J; Zou Y; Rahman JS; Lu B; Massion PP
    Mol Cancer Ther; 2009 Jan; 8(1):101-9. PubMed ID: 19139118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitivity to PI3K and AKT inhibitors is mediated by divergent molecular mechanisms in subtypes of DLBCL.
    Erdmann T; Klener P; Lynch JT; Grau M; Vočková P; Molinsky J; Tuskova D; Hudson K; Polanska UM; Grondine M; Mayo M; Dai B; Pfeifer M; Erdmann K; Schwammbach D; Zapukhlyak M; Staiger AM; Ott G; Berdel WE; Davies BR; Cruzalegui F; Trneny M; Lenz P; Barry ST; Lenz G
    Blood; 2017 Jul; 130(3):310-322. PubMed ID: 28202458
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of the PI3K/Akt/mTOR signaling pathway in diffuse large B-cell lymphoma: current knowledge and clinical significance.
    Majchrzak A; Witkowska M; Smolewski P
    Molecules; 2014 Sep; 19(9):14304-15. PubMed ID: 25215588
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.